Suyang Zhang
Managing Partner @ IDG Capital
Changning, China
Suyang Zhang is a Series B investor at IDG Capital in Changning focused on Software and Health Care. Suyang joined the IDG Capital team in 1994. His background combines extensive expertise in technology and international finance with in-depth ties to China's entrepreneurial community. Suyang successfully launched a series of high-tech projects in the areas of electronics, telecommunications and software in recent years. He has been thecentral programming coordination manager of Shanghai Bell, deputy director of Shanghai factory 520 of Minister of Post & Telecommunication, and General Manager of Hainan Vantone Group Shanghai Company. Suyang earned his bachelor degree in Electronics Engineering from Shanghai University in 1982. He pursued further studies in business management from 1988 to 1990 in Germany, and got EMBA of China Europe International Business School from 1998 to 2000.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 30%
Last updated:
For AI agents: llms.txt
Industries Suyang Zhang invests in
Stages Suyang Zhang invests in
Countries Suyang Zhang invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $8.3M–$14M
- Series B
- $7M–$29M
Investment Focus
Industry
- Software 3 (30%)
- Health Care 3 (30%)
- Biotechnology 3 (30%)
- Information Technology 2 (20%)
- ISP 1 (10%)
Stage
- Series B 3 (30%)
- Angel 2 (20%)
- Series A 2 (20%)
- Series C 2 (20%)
- Seed 1 (10%)
Country
- China 5 (50%)
- United States 3 (30%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Alluxio
|
Alluxio, Inc. (formerly Tachyon Nexus) team consists of the creators and top committers of Alluxio (formerly Tachyon), an open source project from UC Berkeley AMPLab. For the past three years, we have been working to revolutionize the way data is stored, accessed, and managed by focusing on a memory-centric architecture. We believe this newapproach is key to delivering the next generation storage. | $50M / Series C / Nov 16, 2021 | |
Huleen
|
Huleen is committed to opening up application boundaries and bringing together more information. | Angel / Jul 22, 2021 | |
Zenlayer
|
Zenlayer operates as a software-defined network and services provider. It offers bare metal cloud, SD-WAN cloud connect, edge computing, and colocation in over 100 data centers on six continents. Enterprises utilizes Zenlayer’s SDx platforms to instantly enable worldwide connectivity and deliver the user experience.The company was founded in 2014and is headquartered in Diamond Bar, California. | $62M / Series C / May 12, 2021 | |
Vision Medicals
|
Vision Medicals is a provider of pathogenic gene diagnostic services, focusing on infection-precise medical treatment, high-throughput sequencing-based pathogen metagenomics and CRISPR-based rapid diagnosis and other new technologies, effectively improving the detection ability of clinical pathogens and shortening The reporting cycle acceleratedthe development of the infection-accurate medical industry. The company developed a pathogenic nucleic acid enrichment technology with independent intellectual property rights for the detection of pathogenic micronucleic acids in clinical samples. The pathogen macro was established through the accumulation of pathogen detection big data. Genomics intelligent analysis and reporting system. | $28.8M / Series B / Aug 12, 2020 | |
|
Alluxio
|
Alluxio, Inc. (formerly Tachyon Nexus) team consists of the creators and top committers of Alluxio (formerly Tachyon), an open source project from UC Berkeley AMPLab. For the past three years, we have been working to revolutionize the way data is stored, accessed, and managed by focusing on a memory-centric architecture. We believe this newapproach is key to delivering the next generation storage. | $7M / Series B / Apr 16, 2020 | |
Polaris Biology
|
Polaris Biology is a medical technology company specializing in the development and clinical application of cell-level precision diagnostic technology, is dedicated to exploring and studying individual and dynamic changes in tumors at the cellular level, and using this information to support clinical tumor diagnosis and treatment. | $8.3M / Series A / Jan 21, 2019 | |
RootPath
|
RootPath is a Cambridge-based biotechnology company developing a powerful personalized T cell therapy platform that bridges precision medicine and cancer immunotherapy. Their next generation technologies allow us to precisely monitor, modulate and steer the immune system for a revolution in the diagnosis and treatment of cancer. | $7M / Seed / Aug 30, 2018 | |
Triastek
|
Triastek develops 3D printed medicines and the production facilities to manufacture them and has already filed patent applications for its technology. | $15.6M / Series A / Jun 01, 2018 | |
Innovative Cellular Therapeutics
|
Innovative Cellular Therapeutics Co.,Ltd. is a Shanghai-based biotechnology company engaged in research and development of cell therapy. | $28.6M / Series B / Apr 25, 2018 | |
OrigiMed
|
OrigiMed is a medical science and technology transforming company which focuses on developing new technologies and clinical applications for all types of cancer patients. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation, they identify cancer specific molecularmarkers and genomic features to guide targeted or immuno-therapy, ultimately aiming to fortify the evolution of cancer precision medicine in China. | $10M / Angel / Sep 20, 2016 |
Co-Investors
About IDG Capital
IDG Capital is an investment firm that funds early- to growth-stage companies in the technology sector. Today they work with private equity and venture capital fund managers, investment advisors, and business entities from around the world. Their limited partners include many internationally reputable investors, including sovereign wealth funds,pension funds, institutional investors, major charities, university endowments, family offices, and business luminaries.IDG Capital brings a powerful combination of global perspective and local experience to investment management. As long-term value investors, they are highly skilled at mobilizing global resources to address local needs, especially for Inbound and outbound opportunities in China and the rest of Asia. Their highly skilled team has an in-depth understanding of the Chinese market and enjoys close relationships with many influential business leaders.
IDG Capital Contacts
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Suyang Zhang invest in?
Suyang Zhang invests primarily in Software, Health Care and Biotechnology startups, most often at Series B and Angel stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Suyang Zhang's check size?
Suyang Zhang typically joins rounds of $8.3M–$14M at Series A and $7M–$29M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Suyang Zhang participates in.
How do I contact Suyang Zhang?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Suyang Zhang last invest?
The most recent investment recorded for Suyang Zhang closed in Nov 2021. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
